Welcome to our dedicated page for twgl news (Ticker: twgl), a resource for investors and traders seeking the latest updates and insights on twgl stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect twgl's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of twgl's position in the market.
Mycotopia Therapies (OTC Pink: TWGL) announces the formation of PsyBioMed – Australia, a joint venture with Natural MedTech, aiming to conduct clinical trials for psychedelics to treat mental illness. The partnership plans to establish a R&D laboratory and GMP manufacturing facility in Victoria. With over 3 million Australians currently using antidepressants, the initiative focuses on producing cGMP psychedelics and conducting research to validate their efficacy. The Australian government has allocated $15 million for related studies, indicating strong support for the development of psychedelic therapies.
Mycotopia Therapies (OTC Pink: TWGL) has announced the establishment of a new subsidiary, PsyBioMed, which focuses on producing biosynthetic compounds for psychedelics. The aim is to manufacture, license, and sell genetically optimized yeast to produce these compounds at 70-90% lower production costs. PsyBioMed seeks to enhance the affordability and accessibility of psychedelic therapies for mental health disorders and addictions. The joint venture, 51% owned by Mycotopia and 49% by Biomedican, plans to conduct clinical trials to improve drug delivery systems and patient outcomes.
20/20 Global, Inc. (OTC Pink: TWGL) announced its application to FINRA for a corporate name change to Mycotopia Therapies Inc., along with a stock symbol change to MYCO. The firm aims to enhance its brand identity in the psychedelic therapy sector, focusing on treating mental health issues such as anxiety and depression. Additionally, the company is pursuing DTC eligibility to facilitate electronic share transfer for U.S. investors. Current shareholders are not required to take action in response to these changes.
